AMANDA BERGER: Open Payments
NPI 1578335709 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,543 in 72 payments from 15 companies in 2025. Trend: 2023 $44 · 2024 $1,910 · 2025 $1,543
Food & beverage: $1,543
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $270 |
| Alkermes, Inc. | 10 | $250 |
| Neurocrine BioSciences, Inc. | 7 | $181 |
| Teva Pharmaceuticals USA, Inc. | 7 | $143 |
| Almatica Pharma LLC | 5 | $133 |
| Lundbeck LLC | 5 | $104 |
| E.R. Squibb & Sons, L.L.C. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Collegium Pharmaceutical, Inc. | 3 | $62 |
| Indivior Inc. | 2 | $61 |
Products named: VRAYLAR, ARISTADA, INGREZZA, UZEDY, LOREEV XR, REXULTI, COBENFY, CAPLYTA.
Industry payments across MD — which companies pay providers there.
